| Date |
Title |
Rating |
| 2010-07-30 |
FDA lifts hold, allows Geron to proceed with Phase I clinical trial of GRNOPC1 in spinal cord injury |
None |
| 2010-07-30 |
Pivotal PINNACLE trial results of VELCADE in patients with relapsed/refractory MCL released |
None |
| 2010-07-30 |
Anadys Pharmaceuticals reports SVR12 data for ANA598 |
None |
| 2010-07-30 |
SynCo Bio Partners extends collaboration with Versartis |
None |
| 2010-07-30 |
Bio-Path commences dosing in Liposomal Grb-2 Phase I cancer study |
None |
| 2010-07-30 |
Curaxis completes reverse merger with Auto Search Cars |
1 |
| 2010-07-30 |
Anthera initiates PEARL-SC Phase 2b study of A-623 for lupus |
None |
| 2010-07-30 |
Orexigen's Contrave COR-I trial results published online in journal Lancet |
None |
| 2010-07-30 |
Intra-Cellular Therapies ITI-007 Phase Ib/II clinical trial for schizophrenia meets primary endpoint |
5 |
| 2010-07-30 |
ACADIA initiates new pimavanserin Phase III trial for Parkinson's disease psychosis |
None |
| 2010-07-29 |
Anadys second-quarter net loss decreases to $3.0 million |
None |
| 2010-07-29 |
Celgene second-quarter non-GAAP total revenue increases 36% to $850 million |
None |
| 2010-07-29 |
AVEO second-quarter total revenues increase to $15.6 million |
None |
| 2010-07-29 |
Saint Peter's University joins Curemark's clinical trial program for CM-AT autism treatment |
None |
| 2010-07-29 |
Bionovo receives EMA final guidance for advancing Menerba to Phase 3 clinical trials |
None |
| 2010-07-29 |
Rotigotine provides clinically relevant improvements in RLS symptoms: Study |
None |
| 2010-07-29 |
Nymox provides update on NX-1207 Phase 3 program for benign prostatic hyperplasia |
None |
| 2010-07-29 |
Advaxis provides update on survival information from ADXS11-001 phase 1 trial in cervix cancer |
None |
| 2010-07-29 |
Pivotal Phase 3 IMPACT study results of PROVENGE published in New England Journal of Medicine |
None |
| 2010-07-29 |
Generex reports positive trends in ongoing Oral-lyn buccal insulin spray global Phase III trial |
None |
| 2010-07-29 |
Teva Respiratory reports positive results from BDP HFA Nasal Aerosol Phase III trial in seasonal allergic rhinitis |
5 |
| 2010-07-29 |
Etubics enters Phase I trials for next generation vector vaccines |
None |
| 2010-07-29 |
CMX157 shows potential to suppress replication of HIV in Phase 1 clinical trial |
None |
| 2010-07-29 |
Limerick to announce new results from LIM-0705 human trials at 23rd Transplantation Society congress |
None |
| 2010-07-28 |
Intercept signs CRADA with NIDDK for study of obeticholic acid in nonalcoholic steatohepatitis |
5 |
| 2010-07-28 |
Kyowa Hakko Kirin initiates Phase 2 trial of ARQ 197 for gastric cancer: ArQule |
None |
| 2010-07-28 |
Allos reports topline results from Phase 2b trial of FOLOTYN vs erlotinib in advanced NSCLC |
None |
| 2010-07-28 |
Allos reports net loss of $20.0 million for second-quarter 2010 |
None |
| 2010-07-28 |
Pharmasset announces data from PSI-352938 single ascending dose study |
None |
| 2010-07-28 |
BiondVax receives 2010 European Influenza Vaccines Technology Innovation Award |
None |
| 2010-07-28 |
Regeneron second-quarter total revenues increase to $115.9 million |
None |
| 2010-07-28 |
GSK awards NCCN $4 million grant for study of ofatumumab and pazopanib |
None |
| 2010-07-28 |
Antares Pharma reports positive results from Anturol Gel Phase 3 study in overactive bladder patients |
None |
| 2010-07-28 |
InterMune second-quarter total revenue decreases to $5.9 million |
None |
| 2010-07-28 |
MabCure's MAbs 94% accurate in identifying ovarian cancer |
None |
| 2010-07-27 |
Omeros initiates enrollment in OMS302 Phase 2b clinical trial in patients undergoing cataract surgery |
None |
| 2010-07-27 |
Iverson Genetic Diagnostics receives CMS approval for Warfarin clinical study |
None |
| 2010-07-27 |
Study on interactions between new antitubercular drug candidates SQ109 and TMC207 |
None |
| 2010-07-27 |
Idenix second-quarter total revenues decrease to $1.3 million |
None |
| 2010-07-26 |
QRxPharma reports positive outcome of European Scientific Advice meetings on MoxDuo IR pain therapy |
None |
| 2010-07-26 |
Seaside Therapeutics reports positive data from STX209 Phase 2 study in fragile X syndrome |
None |
| 2010-07-26 |
Can-Fite's CF102 decreases HCV viral load in liver cancer patients |
5 |
| 2010-07-26 |
Hospira commences EPO Phase I U.S. clinical trial in renal dysfunction patients with anemia |
None |
| 2010-07-26 |
AVEO's initiation of AV-299 Phase 2 trial for lung cancer triggers $750,000 milestone payment to XOMA |
None |
| 2010-07-26 |
Onyx reports positive results from carfilzomib Phase 2b 003-A1 study in multiple myeloma |
None |
| 2010-07-26 |
Vical's prophylactic Vaxfectin-formulated pDNA vaccine effective against HSV-2 in animal model |
5 |
| 2010-07-26 |
ESC concerned over interpretation of JUPITER sub-analysis trial results about HDL cholesterol |
5 |
| 2010-07-26 |
Cerenis, Novasep awarded French Government funding for development of CER-001 HDL mimetic |
None |
| 2010-07-26 |
L2FU reports 100% recovery of recent study's lost clinical trial patients |
None |
| 2010-07-26 |
North Shore-LIJ Health System seeks oropharynx patients for phase I clinical trial |
None |
| 2010-07-26 |
Experimental treatment for sickle cell disease enters Phase 3 clinical trials |
2 |
| 2010-07-23 |
First patient enrolled in Phase 3 SyNAPSe study of BHR-100 for TBI |
4 |
| 2010-07-23 |
Tarsa Therapeutics completes patient enrollment in Phase III ORACAL trial of oral calcitonin |
None |
| 2010-07-23 |
Update on Phase III Study of oral calcitonin for treatment of osteoarthritis |
None |
| 2010-07-23 |
Novartis, Nordic Bioscience to continue oral calcitonin Phase III study in osteoarthritis patients |
None |
| 2010-07-23 |
Early HAART during TB treatment prolongs survival of untreated HIV-infected adults: CAMELIA study |
None |
| 2010-07-23 |
Boehringer Ingelheim's VERxVE study of nevirapine meets primary endpoint |
None |
| 2010-07-23 |
NPS completes patient randomization in GATTEX Phase 3 study for PN dependent short bowel syndrome |
None |
| 2010-07-23 |
Cytrx’s tamibarotene achieves molecular complete remission in advanced acute promyelocytic leukemia |
None |
| 2010-07-23 |
Independent DSMB recommends Inhibitex to complete FV-100 Phase II clinical trial for shingles |
None |
| 2010-07-22 |
Tibotec reports Phase 3 trial results of TMC278 vs. EFV in treatment-naive HIV-1-infected adults |
None |
| 2010-07-22 |
Achillion nominates ACH-2928 NS5A clinical candidate for treatment of HCV |
None |
| 2010-07-22 |
Tarsa completes enrollment in Phase III ORACAL trial for postmenopausal osteoporosis |
None |
| 2010-07-22 |
Merrimack, sanofi-aventis initiate dosing in MM-121 and exemestane combination Phase 2 breast cancer study |
None |
| 2010-07-22 |
Repros granted IRB approval to commence low dose Proellex study |
None |
| 2010-07-22 |
Somaxon's Silenor Phase 3 clinical data accepted for publication in Sleep, Sleep Medicine journals |
None |
| 2010-07-22 |
Fera acquires investigational new drug for treatment of fungal otitis externa |
None |
| 2010-07-22 |
Onyx begins Phase 3 trial of carfilzomib in combination with lenalidomide, dexamethasone for relapsed myeloma |
4 |
| 2010-07-22 |
Ampio Pharmaceuticals commences Optina Phase II clinical trial for diabetic macular edema |
4 |
| 2010-07-21 |
AMRI initiates enrollment for Phase I study of ALB-127158 for obesity |
None |
| 2010-07-21 |
Shionogi-ViiV Healthcare to advance '572 inhibitor into Phase III clinical trials |
None |
| 2010-07-21 |
NovaBay reports positive results from NVC-422 Phase 2a proof-of-concept clinical trial for impetigo |
None |
| 2010-07-21 |
PROLOR Biotech initiates Phase II clinical trial of biobetter version of human growth hormone |
None |
| 2010-07-21 |
AiCuris presents preclinical data on AIC246 anti-HCMV drug at International Herpesvirus Workshop |
5 |
| 2010-07-21 |
AIDS 2010: Study finds microbicide containing HIV drug lowers infection risk in women by 39% |
None |
| 2010-07-21 |
Major turning point in antiepileptic drug testing, development |
None |
| 2010-07-20 |
Arcion reports top-line results from ARC-4558 Phase 2b clinical trial for painful diabetic neuropathy |
None |
| 2010-07-20 |
Archer Biosciences initiates third drug-escalation cohort in TPI-287 trial for metastatic melanoma |
None |
| 2010-07-20 |
KAI Pharmaceuticals completes enrollment in Phase 1 study of KAI-4169 for SHPT |
None |
| 2010-07-20 |
Seattle Genetics, Agensys commence ASG-5ME ADC phase I clinical trial for metastatic pancreatic cancer |
None |
| 2010-07-20 |
Tenofovir gel reduces HIV by 39% in women: CAPRISA 004 study |
None |
| 2010-07-20 |
Global Campaign for Microbicides praises CAPRISA 004 gel trial for women's HIV prevention |
None |
| 2010-07-20 |
Aegera reports data from Phase 1 portion of combination AEG35156 Phase 1-2 study for primary liver cancer |
None |
| 2010-07-20 |
AVAC applauds CAPRISA 004 microbicide gel trial for preventing sexual transmission of HIV infection |
None |
| 2010-07-20 |
Argos' Arcelis immunotherapy reduces viral load in interim analysis of Phase 2 HIV trial |
None |
| 2010-07-20 |
Researchers make scientific breakthrough in fight against HIV, genital herpes with a vaginal gel |
None |
| 2010-07-20 |
USAID Administrator issues statement on CAPRISA 004 trial for preventing HIV infection in women |
None |
| 2010-07-20 |
MDMA (Ecstasy) holds promise for chronic treatment-resistant PTSD |
None |
| 2010-07-20 |
Phase 3 study: Tapentadol ER lowers incidence of gastrointestinal adverse events |
None |
| 2010-07-20 |
CytRx updates on progress in clinical development of bafetinib in three oncology indications |
None |
| 2010-07-20 |
Pfizer suspends chronic low back pain, diabetic peripheral neuropathy studies in tanezumab clinical program |
None |
| 2010-07-20 |
ZIOPHARM Oncology commences palifosfamide Phase III clinical trial for metastatic soft tissue sarcoma |
None |
| 2010-07-20 |
Abbott presents 48-week PROGRESS study results at 28th International AIDS Conference |
None |
| 2010-07-20 |
Benefits of drug L-methionine for neurogenic bladder disorders unclear |
None |
| 2010-07-19 |
Amira achieves two clinical development milestones in FLAP program for asthma |
None |
| 2010-07-19 |
Oncolytics Biotech receives Canadian approval for combination REOLYSIN Phase 3 trial in head, neck cancer |
None |
| 2010-07-19 |
Geron commences enrollment in imetelstat Phase 2 clinical trial for NSCLC |
5 |
| 2010-07-19 |
Phase 2 CUBICIN study for prosthetic joint infections meets primary endpoint |
None |
| 2010-07-19 |
Phase II data on Genetic Immunity's DermaVir vaccine to be presented at XVIII International AIDS Conference |
5 |
| 2010-07-19 |
ViroStatics to present VS411 Phase II dose-ranging trial data at International AIDS Conference in Vienna |
1 |
| 2010-07-19 |
FIT Biotech to present results of FIT-06 Phase II clinical trial at XVIII International AIDS 2010 Conference |
1 |
| 2010-07-17 |
Pacific Shore releases clinical trial results for Burner Balm lip balm |
None |
| 2010-07-17 |
Amgen granted FDA priority review designation for denosumab BLA |
None |
| 2010-07-16 |
VIVUS disappointed with FDA Advisory Committee's vote on QNEXA for obesity treatment |
None |
| 2010-07-16 |
JDD publishes long-term efficacy and tolerability study of PyratineXR Moisturizing Lotion |
None |
| 2010-07-16 |
Noscira presents results of Nypta Phase IIa clinical trial for AD at ICAD 2010 |
None |
| 2010-07-15 |
QR Pharma to present positive clinical data from mechanism of action study in MCI at ICAD 2010 |
2 |
| 2010-07-15 |
Positive microplasmin Phase II trial results published in journal Retina |
None |
| 2010-07-15 |
Scientists comment on two clinical trials that use Rituximab to treat small-vessel vasculitis |
None |
| 2010-07-15 |
PPMD to provide grant to clinical sites participating in Phase 2 study of ACE-031 |
None |
| 2010-07-15 |
Two patents issued for GlycoMimetics lead drug candidate, related compounds |
None |
| 2010-07-15 |
Enrollment complete in Nabi's first NicVAX Phase III clinical trial for nicotine addiction |
None |
| 2010-07-15 |
Aeterna Zentaris' partner Keryx receives FDA orphan-drug designation for perifosine in neuroblastoma |
None |
| 2010-07-14 |
Aastrom commences extension study for control patients from Phase 2 IMPACT-DCM clinical trial |
None |
| 2010-07-14 |
Phase 1/2 clinical study of bepotastine besilate nasal spray initiated for seasonal allergic rhinitis |
None |
| 2010-07-14 |
Presidio Pharmaceuticals completes Phase 1a clinical trial of PPI-461 in healthy subjects |
4 |
| 2010-07-14 |
Supernus initiates SPN812 Phase IIa clinical trial for ADHD in adults |
None |
| 2010-07-14 |
ChemGenex agrees with FDA on potential regulatory path to progress OMAPRO for CML |
None |
| 2010-07-13 |
Fredericksburg Oncology invites participants for new metastatic melanoma clinical trial |
None |
| 2010-07-13 |
SCENESSE reduces, prevents phototoxic reactions experienced by EPP patients in Phase III trial |
None |
| 2010-07-13 |
MAP Pharmaceuticals reports results from LEVADEX PK and safety clinical trial in smokers, non-smokers |
None |
| 2010-07-13 |
Innocoll submits SPA for phase 3 clinical trial of Cogenzia for adjuvant treatment of infected diabetic foot ulcers |
None |
| 2010-07-13 |
EntreMed announces publication of preclinical data for ENMD-2076 |
None |
| 2010-07-13 |
Clinical trial initiated to evaluate LibiGel on cognitive function in menopausal women |
None |
| 2010-07-13 |
AlphaRx reports positive preclinical results of GAI-122 injectable nanoemulsion for Acute Ischemic Stroke |
None |
| 2010-07-13 |
Biodel reports preclinical test results of BIOD620 glucose-regulated or "smart" basal insulin product candidate |
None |
| 2010-07-13 |
BioSpecifics' partner Auxilium provides update on XIAFLEX |
None |
| 2010-07-12 |
Report on program to develop, test nasally delivered H5N1 vaccine filed with Japan's MHLW |
None |
| 2010-07-12 |
Novelos reports positive results from NOV-002 Phase 2 neoadjuvant breast cancer trial |
None |
| 2010-07-12 |
Reata funds second pivotal trial of bardoxolone with $78 million equity financing |
None |
| 2010-07-12 |
Medivir reports 24-week interim Phase 2b results of TMC435 in treatment-naïve patients with HCV genotype-1 |
None |
| 2010-07-12 |
Interim progress from Phase III TeloVac study of GV1001 vaccine announced |
None |
| 2010-07-12 |
Biogen Idec, Swedish Orphan Biovitrum present results from rFIXFc Phase 1/2a study in hemophilia B |
5 |
| 2010-07-12 |
bitop's Ectoin allergy nasal spray reduces symptoms of acute allergic rhinitis in two-week crossover study |
None |
| 2010-07-12 |
Biogen Idec, Swedish Orphan Biovitrum announce advancement of rFVIIIFc into registrational study |
None |
| 2010-07-12 |
Study results show no improvement in overall survival for combination of gemcitabine and Amplimexon |
None |
| 2010-07-12 |
Mesoblast schedules formal meeting with FDA to discuss proposed Phase 3 clinical trial program |
None |
| 2010-07-09 |
Phase III study results of imiquimod creams for treatment of EGW presented at HPV Conference |
None |
| 2010-07-09 |
Phase II trial results of TB-402 presented at International Congress on Thrombosis |
None |
| 2010-07-09 |
Bayer HealthCare to present BAY86-6150 rFVIIa Phase I clinical data at XXIX WFH International Congress |
None |
| 2010-07-08 |
Rockwell Medical completes End of Phase II meeting with FDA regarding SFP |
3 |
| 2010-07-08 |
Advanced Life Sciences announces positive results from preclinical studies of Restanza IV |
None |
| 2010-07-08 |
Kiadis Pharma receives FDA approval for IND to start pivotal clinical study for ATIR |
None |
| 2010-07-08 |
Selvita, Orion collaborate to develop and commercialize SEL103 Alzheimer’s disease program |
None |
| 2010-07-08 |
Nymox reports positive new results from pooled analysis of NX-1207 clinical trials for BPH |
None |
| 2010-07-08 |
GSK, XenoPort disappointed with GSK1838262/XP13512 phase 2b study for migraine headaches |
None |
| 2010-07-08 |
Olaparib shows promising results against inherited forms of breast and ovarian cancer |
None |
| 2010-07-07 |
NOXXON to commence multiple ascending dose study of MCP-1 targeting anti-inflammatory Spiegelmer NOX-E36 |
None |
| 2010-07-07 |
Neoprobe initiates third multi-center Phase 3 clinical study of Lymphoseek |
None |
| 2010-07-07 |
Alnylam Pharmaceuticals initiates dosing in Phase I human clinical study with ALN-TTR01 |
None |
| 2010-07-07 |
Nile completes dosing in CD-NP Phase II study for acute decompensated heart failure |
None |
| 2010-07-07 |
Data on activity of Nektar's NKTR-102 in gastrointestinal cancer presented at ESMO 12th World Congress |
None |
| 2010-07-07 |
Combination of Biothera's Imprime PGG and Erbitux doubles response rate in colorectal cancer patients |
None |
| 2010-07-07 |
Capstone Therapeutics to continue AZX100 Phase 2a trial in dermal scarring to planned 12-month endpoints |
None |
| 2010-07-07 |
Genentech submits BLA for trastuzumab-DM1 in advanced HER2-positive breast cancer |
None |
| 2010-07-07 |
Debiopharm's achievement of Phase I milestone in Debio 0932 trial triggers $3M milestone payment to Curis |
None |
| 2010-07-07 |
Initial Phase II study results of ofatumumab in patients with RRMS announced |
None |
| 2010-07-07 |
FDA accepts DBV Technologies' IND for clinical study of VIASKIN for desensitization to peanut allergy |
None |
| 2010-07-07 |
Phase Ia clinical trial of SYL040012 for treating elevated intraocular pressure, glaucoma completed |
None |
| 2010-07-07 |
Crux Biomedical commences enrollment in Retrieve 2 pivotal U.S. IDE trial of new Vena Cava Filter |
None |
| 2010-07-07 |
PuraMed BioScience completes clinical study of LipiGesic M for treating acute migraine |
None |
| 2010-07-07 |
FDA grants Angion Biomedica's BB3 therapeutic Fast Track and Orphan Drug product designations |
5 |
| 2010-07-06 |
Adeona completes $1 million equity financing and provides update on Zinthionein ZC clinical study |
2 |
| 2010-07-06 |
CTI submits expanded PIP to EMEA for pixantrone MAA for relapsed or refractory, aggressive NHL |
None |
| 2010-07-06 |
Nottingham researchers undertake new clinical trial on hearing loss |
None |
| 2010-07-06 |
EC approves change in posology of Circadin from 3 weeks to 3 months of treatment |
None |
| 2010-07-02 |
Study: ONGLYZA and metformin improve HbA1c levels for adult patients with type 2 diabetes at 76-weeks |
None |
| 2010-07-02 |
Shire presents positive data from TKT-025 EXT Phase I/II study for VPRIV in type 1 Gaucher disease patients |
None |
| 2010-07-02 |
Chelsea reports positive outcome from DMC review of droxidopa Phase II trial in fibromyalgia |
1.5 |
| 2010-07-02 |
QR Pharma to present clinical data from mechanism of action study in MCI patients at ICAD 2010 |
None |
| 2010-07-02 |
Compugen's CGEN-15001 recombinant fusion protein abolishes spontaneous relapses in animal model of MS |
None |
| 2010-07-02 |
Genentech's second Phase III ICON7 study of Avastin in ovarian cancer meets primary endpoint |
None |
| 2010-07-01 |
ThromboGenics to present microplasmin Phase III trial data at 28th ASRS and 10th EURETINA Congress |
None |
| 2010-07-01 |
Studies on VIAject and Vialog presented at 70th American Diabetes Association sessions |
None |
| 2010-07-01 |
Oxycyte PFCE decreases mortality after onset of decompression sickness in porcine model study |
None |
| 2010-07-01 |
Study results of triple combination therapy in patients with diabetes and hypertension presented at ADA 2010 |
None |
| 2010-07-01 |
Afinitor more than doubles progression-free survival in advanced pancreatic NET: Study |
None |
| 2010-07-01 |
Sepracor announces preliminary results from OMNARIS HFA Phase III study for seasonal allergic rhinitis |
None |
| 2010-07-01 |
Evotec commences EVT 101 proof-of-concept Phase II study in treatment-resistant depression |
None |
| 2010-07-01 |
CBio achieves recruitment milestone in XToll clinical trial |
None |
| 2010-07-01 |
Biospherics acquires worldwide patent rights to Dtagatose from UKRF |
None |
| 2010-07-01 |
XOMA reaches enrollment goal of 325 patients for Phase 2b clinical trial of XOMA 052 |
None |
| 2010-07-01 |
Eisai reports preliminary results from Dacogen for Injection Phase III study in AML |
None |
| 2010-07-01 |
Threshold Pharmaceuticals initiates Phase 2 clinical trial of TH-302 in patients with first line pancreatic cancer |
None |
| 2010-07-01 |
Cubist commences enrollment in Phase 2 study of CXA-201 for complicated intra-abdominal infections |
None |